Predicting response to immune checkpoint inhibitor plus chemotherapy in EGFR-mutant lung adenocarcinoma following first-generation TKI resistance: a multicenter deep learning study - Top-Institutions - MDSpire

Assessing Treatment Response to Immune Checkpoint Inhibitors Combined with Chemotherapy in EGFR-Mutant Lung Adenocarcinoma After Resistance to First-Generation TKIs: Insights from a Multicenter Deep Learning Analysis

  • By

  • Shuai Qie

  • Yasong Shi

  • Jingyun Li

  • Sicong Jia

  • Xiaoping Yin

  • July 17, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    GARNET trial
    GARNET trial

    N/A, N/A

    Key Differentiators

    • Oncology

  • #2

    10 institutions in the United States and Europe
    10 institutions in the United States and Europe

    N/A, N/A

    Key Differentiators

    • Oncology

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Oncology

  • #5

    Gustave Roussy
    Gustave Roussy

    Villejuif, Île-de-France

    Key Differentiators

    • Oncology

Original Source(s)

Predicting response to immune checkpoint inhibitor plus chemotherapy in EGFR-mutant lung adenocarcinoma following first-generation TKI resistance: a multicenter deep learning study

  • by Shuai Qie, Yasong Shi, Jingyun Li, Sicong Jia, Xiaoping Yin

  • July 17, 2026

Related Content

A prehabilitation-enhanced nomogram for predicting early pulmonary recovery failure after lung tumor surgery: development and multicenter validation

Late radiation necrosis following stereotactic radiosurgery after COVID-19 vaccination: a case report and hypothesis of immune-mediated inflammatory activation

Cost-Effectiveness of Universal Low-Dose Computed Tomographic Lung Cancer Screening in Singapore